| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/02/2006 | CA2577926A1 Nutritional composition comprising immunoglobulins and oligosaccharides |
| 03/02/2006 | CA2577857A1 Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases |
| 03/02/2006 | CA2577846A1 Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1 |
| 03/02/2006 | CA2577837A1 Diarylsulfones as 5-ht2a antagonists |
| 03/02/2006 | CA2577782A1 Pyrrolo-naphthyl acids as pai-1 inhibitors |
| 03/02/2006 | CA2577780A1 Multi-functional biocompatible coatings for intravascular devices |
| 03/02/2006 | CA2577752A1 Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| 03/02/2006 | CA2577748A1 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives as crth2 antagonists |
| 03/02/2006 | CA2577677A1 Modulators of muscarinic receptors |
| 03/02/2006 | CA2577676A1 Process for production of microbial fat/oil containing discretional amount of diacylglycerol and said fat/oil |
| 03/02/2006 | CA2577631A1 Methods and compositions for treating allergic inflammation |
| 03/02/2006 | CA2577528A1 Heterocyclic antiviral compounds |
| 03/02/2006 | CA2577526A1 Antiviral 4'-azido-nucleosides |
| 03/02/2006 | CA2577511A1 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase ie |
| 03/02/2006 | CA2577442A1 Pde5 inhibitor compositions and methods for treating cardiac indications |
| 03/02/2006 | CA2577420A1 Lonidamine analogues and their use in male contraception and cancer treatment |
| 03/02/2006 | CA2577373A1 Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
| 03/02/2006 | CA2577361A1 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle |
| 03/02/2006 | CA2577350A1 Vaginal cream compositions, kits thereof and methods of using thereof |
| 03/02/2006 | CA2577251A1 Pyrimidine derivatives |
| 03/02/2006 | CA2577191A1 4-heteroarylmethyl substituted phthalazinone derivatives |
| 03/02/2006 | CA2577177A1 Oxopiperidine derivatives, preparation and therapeutic use thereof |
| 03/02/2006 | CA2577100A1 Chemical compounds |
| 03/02/2006 | CA2577089A1 Sigma receptor inhibitors |
| 03/02/2006 | CA2577084A1 Bicyclononene derivatives as renin inhibitors |
| 03/02/2006 | CA2577061A1 Histamine h3 receptor agents, preparation and therapeutic uses |
| 03/02/2006 | CA2576747A1 Benzoxazepine derivatives as selective estrogen receptor modulators |
| 03/02/2006 | CA2576659A1 Solid and crystalline ibandronate sodium and processes for preparation thereof |
| 03/02/2006 | CA2576562A1 Nutritional composition comprising galactose-containing indigestible oligosaccharides |
| 03/02/2006 | CA2576552A1 Eye drops for the treatment of dry eye |
| 03/02/2006 | CA2576465A1 Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 03/02/2006 | CA2576247A1 Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, in staphylococcus aureus |
| 03/02/2006 | CA2576186A1 T type calcium channel blockers and the treatment of diseases |
| 03/02/2006 | CA2576168A1 Mitotic kinesin inhibitors |
| 03/02/2006 | CA2576159A1 Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases |
| 03/02/2006 | CA2576094A1 Ligand-dependant activation of nur77 and uses thereof |
| 03/02/2006 | CA2575887A1 Rapamycin polymorph ii and uses thereof |
| 03/02/2006 | CA2575804A1 Pteridinones used as plk (polo like kinase) inhibitors |
| 03/02/2006 | CA2575684A1 Pulmonary delivery of inhibitors of phosphodiesterase type 5 |
| 03/02/2006 | CA2575680A1 Cyclic amide & ester pyrazinoylguanidine sodium channel blockers |
| 03/02/2006 | CA2575670A1 Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers |
| 03/02/2006 | CA2575645A1 Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| 03/02/2006 | CA2575461A1 The use of n-aryl diazaspiracyclic compounds in the treatment of addiction |
| 03/02/2006 | CA2575200A1 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease |
| 03/02/2006 | CA2575078A1 Lercanidipine salts |
| 03/02/2006 | CA2574517A1 Amino-tropane derivatives, preparation thereof and therapeutic use thereof |
| 03/02/2006 | CA2574454A1 Aminopiperidine derivatives, preparation thereof and use thereof as melanocortin receptor agonists |
| 03/02/2006 | CA2574345A1 Use of a fatty acid for preparing a topical composition for allaying inflammatory reactions due to venemous hymenoptera stings |
| 03/02/2006 | CA2573446A1 4-arylmorpholin-3-one derivatives, preparation and therapeutic use thereof |
| 03/02/2006 | CA2573371A1 Pyrimidines as plk inhibitors |
| 03/02/2006 | CA2573314A1 Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof |
| 03/02/2006 | CA2573310A1 Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof |
| 03/02/2006 | CA2573125A1 Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
| 03/02/2006 | CA2571132A1 Novel compounds having an anti-bacterial activity |
| 03/02/2006 | CA2565803A1 Benzoureas having anti-diabetic activity |
| 03/02/2006 | CA2564898A1 Risedronate compositions and their methods of use |
| 03/02/2006 | CA2564224A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof |
| 03/02/2006 | CA2515320A1 S-triazine compounds possessing two substituents chosen from bulky para-aminobenzalmalonate and para-aminobenzalmalonamide groups and an aminobenzoate subsituent; compounds and uses |
| 03/01/2006 | EP1630165A1 [1,2,4 ]triazolo [1,5-a]pyrimidin-2-ylurea derivative and use thereof |
| 03/01/2006 | EP1630164A1 Pyrazolopyrimidinones as phosphodiesterase inhibitors |
| 03/01/2006 | EP1630163A1 Dihydropteridinones, methods for their preparation and their use as drugs |
| 03/01/2006 | EP1630160A1 The isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same as the effective constituents |
| 03/01/2006 | EP1630159A1 5-HT7 receptor antagonists |
| 03/01/2006 | EP1630158A1 5-HT7 receptor antagonists |
| 03/01/2006 | EP1630156A1 Sertraline hydrochloride polymorphs |
| 03/01/2006 | EP1629856A2 Solution for peritoneal dialysis and two-chambers bag containing it |
| 03/01/2006 | EP1629853A1 Method for preparing powder exhibiting low susceptibility to electrification |
| 03/01/2006 | EP1629850A1 Nutritional composition comprising indigestible oligosaccharides |
| 03/01/2006 | EP1629845A2 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| 03/01/2006 | EP1629844A1 A longterm delivery system with controlled initial burst |
| 03/01/2006 | EP1629843A2 Reboxetine for treating chronic fatigue syndrome |
| 03/01/2006 | EP1629842A1 Topical application of thiazolyl amides |
| 03/01/2006 | EP1629841A1 Antidepressants or food and drinks for antidepression |
| 03/01/2006 | EP1629840A1 Amino acid composition and fluid replacement |
| 03/01/2006 | EP1629839A1 Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain |
| 03/01/2006 | EP1629838A1 Footcare product with glycerin and no added water |
| 03/01/2006 | EP1629837A1 Antistress agent |
| 03/01/2006 | EP1629834A1 Sustained release pharmaceutical composition of tolterodine |
| 03/01/2006 | EP1629833A1 Process for producing microparticle |
| 03/01/2006 | EP1629832A1 A pharmaceutical formulation comprising human growth hormone, an amino acid and a non-ionic detergent |
| 03/01/2006 | EP1629729A2 Use of a crosslinked or inhibited starch product |
| 03/01/2006 | EP1629728A1 Use of chemically modified starch product |
| 03/01/2006 | EP1629727A1 Composition containing fermentable polysaccharides |
| 03/01/2006 | EP1629284A2 Methods for identifying modulators of kinesin activity |
| 03/01/2006 | EP1629283A2 Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases |
| 03/01/2006 | EP1629010A1 Treatment with anti-vegf antibodies |
| 03/01/2006 | EP1628992A2 Methods of modulating metastasis and skeletal related events resulting from metastases |
| 03/01/2006 | EP1628990A1 Novel 14 and 15 membered ring compounds |
| 03/01/2006 | EP1628989A1 Novel 14 and 15 membered-ring compounds |
| 03/01/2006 | EP1628988A1 Novel 14 and 15 membered-ring compounds |
| 03/01/2006 | EP1628986A2 Synthesis of high molecular weight iron-saccharidic complexes |
| 03/01/2006 | EP1628984A1 Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use |
| 03/01/2006 | EP1628981A2 Bicyclicpyrimidones and their use to treat diseases |
| 03/01/2006 | EP1628980A1 6-arylmethyl-substituted pyrazolopyrimidines |
| 03/01/2006 | EP1628979A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors |
| 03/01/2006 | EP1628978A2 Triaza-spiro compounds as nociceptin analogues and uses thereof |
| 03/01/2006 | EP1628977A2 ANTIBIOTIC TETRAHYDRO-b-CARBOLINE DERIVATIVES |
| 03/01/2006 | EP1628976A1 Novel pyridopyrazines and use thereof as kinase inhibitors |
| 03/01/2006 | EP1628974A2 Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (tace) |
| 03/01/2006 | EP1628973A2 Processes for preparation of ziprasidone |